DOCSLIB.ORG

Galderma Laboratories and Singapore Immunology Network Collaborate to Deepen Understanding of Acne

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Galderma Laboratories and Singapore Immunology Network Collaborate to Deepen Understanding of Acne MEDIA RELEASE 18 OCTOBER 2011 GALDERMA LABORATORIES AND SINGAPORE IMMUNOLOGY NETWORK COLLABORATE TO DEEPEN UNDERSTANDING OF ACNE 1. A*STAR’s Singapore Immunology Network (SIgN) and Galderma Laboratories, a Swiss pharmaceutical company and world leader in the research and development of dermatology products, have signed an agreement to study how acne develops in the skin. The research may lead to new treatments for acne, which has a global market estimated to be worth US$3 billion. Acne – actually an immune condition 2. The collaboration aims to elucidate previously unknown immune mechanisms behind acne – a chronic disorder caused by inflammation of the hair follicles and sebum-producing glands in the skin. Acne is characterised by infection with the bacterium Propionibacterium acnes (P. acnes) and its associated inflammatory response, which causes lesions on the skin. Current treatment involves killing P. acnes with bactericidal agents such as benzoyl peroxide and oral or topical antibiotics. 3. Exactly how this inflammation in the skin develops is not clear, but it may be induced by a combination of hormonal, microbiological and immunological factors. Understanding the immune mechanisms that contribute to the development of the inflammatory phase of acne will help scientists to identify molecular targets for the treatment of this condition at its roots. 4. Led by SIgN Principal Investigator, Dr Florent Ginhoux, a team of scientists will develop and characterise a mouse model of P. acnes infection to investigate the roles of different types of immune cells, known as dendritic cells 1, 1 Dendritic cells are immune cells found in mammalian tissues in contact with the external environment, such as the skin, the inner lining of the nose, lungs, stomach and intestines. They process antigen (foreign) material that enters the body and present it on their cell surface to activate other cells of the immune system. Some photographs of dentritic cells are at the Annex . 1 and their interactions in responding to the bacteria. Said Dr Ginhoux, “A better understanding of the cellular and molecular mechanisms leading to a disease should facilitate the design of effective drugs to treat it. Ultimately, we hope to identify a means to develop novel treatments of this condition that affects millions worldwide and is also known to have adverse psychological effects.” Mounting a multi-disciplinary approach 5. A coordinated effort in multiple areas will be required in this study to battle acne and its physical and psychological scars. Over the next two years, the project will be supported by several research groups at SIgN with expertise in flow cytometry, cell imaging, bioinformatics, and gene expression techniques. SIgN’s critical mass of 200 immunologists at its premises in the Biopolis research hub will facilitate the rapid generation and pooling of research data. Furthermore, a dedicated project management team at SIgN will ensure the coordination of the various groups to achieve the project milestones. 6. Said Galderma’s Research Director T. Portal, “This partnership will bring added insight into physiopathological processes of acne to complement our array of approaches, and will clearly bring direct value toward our project portfolio. Equally important is the opportunity to partner with a world-class institution, with high level scientists and technical capabilities: this further illustrates the ambition of Galderma to be recognized as the innovation leader in dermatology, in large part through a network of leading scientific partners.” Win-win collaborations with industry 7. This industry partnership is SIgN’s 11 th since its inauguration in 2008. Said Chairman of SIgN, Prof Philippe Kourilsky, “This collaboration with Galderma will create new synergies from the pooling of Galderma’s specialised knowledge of skin conditions with SIgN’s expertise in cellular and molecular immunology research. We will continue to leverage our unique combination of capabilities to pursue high-impact collaborations with industry for the benefit of mankind.” Added Dr Luigi Ricciardi, Director of Industry and Business Development at SIgN, “This is a further step towards the establishment of world- class translational research activities in Singapore.” ________________________________________________________________ For media queries, please contact: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) 2 Ms Adela Foo Senior Officer, Corporate Communications Email: [email protected] Phone: (+65) 6826 6218 GALDERMA Corporate Press inquiries: Peter Nicholson, Corporate Development Director Email: [email protected] Phone: +33 (0)1 58 86 46 78 About the Singapore Immunology Network (SIgN) The Singapore Immunology Network (SIgN), officially inaugurated on 15 January 2008, is a research consortium under the Agency for Science, Technology and Research (A*STAR)’s Biomedical Research Council. The mandate of SIgN is to advance human immunology research and participate in international efforts to combat major health problems. Since its launch, SIgN has grown rapidly and currently includes 200 scientists from 25 different countries of the world working under 24 renowned principal investigators. At SIgN, researchers investigate immunity during infections and inflammatory conditions including cancer and are supported by cutting edge technological research platforms and core services. Through this, SIgN aims to build a strong platform in basic human immunology research for better translation of research findings into clinical applications. SIgN also sets out to establish productive links with local and international institutions, and encourage the exchange of ideas and expertise between academic, industrial and clinical partners and thus contribute to a vibrant research environment in Singapore. For more information about SIgN, please visit www.sign.a-star.edu.sg. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences and physical sciences and engineering research institutes, and six consortia & centres, located in Biopolis and Fusionopolis as well as their immediate vicinity. A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, hospitals, research centres, and with other local and international partners. For more information on A*STAR, please visit www.a-star.edu.sg. About Galderma 3 A COMPANY EXCLUSIVELY DEDICATED TO DERMATOLOGY Our Activity Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. One of the leading investor in dermatology research, with global state-of-the-art R&D facilities, Galderma focuses exclusively on therapeutic and aesthetic innovations. Our Ambition Committed to the future of dermatology, Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians. Key Figures Number 1 * in the D class (Dermatology) and Number 1* in the D + J1A (Systemic Acne/Rosacea) + J2A (Systemic Onychomycosis) class , Sales in 2010: 1.2 billion euro , an increase of 16.1% over 2009 at comparable rates, Worldwide sales breakdown** : - North America: 58% - Europe, Middle-East - Africa, Asia-Pacific & Latin America: 42% 31 affiliates , More than 3 200 people throughout the world, Products distributed in over 70 countries , Approximately 20% of revenues invested to discover and develop new drugs and access innovative technologies. 1 700 scientific publications, more than 550 inventions and 5 500 patent applications and patents. Global Organization Headquarters: Lausanne (Switzerland), R&D centers: France, USA and Japan Manufacturing sites: France, Canada and Brazil Affiliates: in the major countries of the globe’s five continents (Europe, Africa, Australia, Asia, Americas), Joint-venture between Nestlé and L’Oréal created in 1981. Conditions and Products Therapeutic areas: Acne, rosacea, psoriasis/steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer, medical solutions for skin senescence. 4 Strategic products: Epiduo (acne), Oracea (rosacea), Clobex (psoriasis), Azzalure/Dysport (skin senescence), Differin (acne), Cetaphil (therapeutic skin care line), Loceryl (onychomycosis), Rozex/Metro (rosacea), Silkis/Vectical (psoriasis), Metvix (skin cancer), Tri-Luma (pigmentary disorders), Emervel (skin senescence). For more information, please visit our site : www.galderma.com 5 ANNEX Visuals : pictures of dentritic cells Picture 1: Scanning electron microscope (SEM) image of a human skin dendritic cell , highlighting its unique morphology with branch-like ramifications, called dendrites. Picture 2: Confocal microscope image of a mouse Langerhans cell , a dendritic cell found in the epidermis (appears green) . Surrounding it are keratinocytes ( main skin cells forming the epidermis ) with their nuclei stained to appear blue. 6.
Load more

Recommended publications
  • Full-Year 2015: 4.2% Organic Growth, Trading Operating Profit Margin up 10 Basis Points in Constant Currencies
    Press release Vevey, 18 February 2016 Follow today's event live 08:30 CET Full-year results conference webcast Full details: www.nestle.com/media/mediaeventscalendar/allevents/2015-full-year-results Full-Year 2015: 4.2% organic growth, trading operating profit margin up 10 basis points in constant currencies 4.2% organic growth and 2.2% real internal growth Sales of CHF 88.8 billion, foreign exchange impact of -7.4% Trading operating profit margin of 15.1%, up 10 basis points in constant currencies Underlying earnings per share up 6.5% in constant currencies Strong operating cash flow at CHF 14.3 billion Proposed dividend increase to CHF 2.25 per share 2016 outlook: organic growth in line with 2015 with improvements in margins and underlying earnings per share in constant currencies, and capital efficiency Paul Bulcke, Nestlé CEO: “In 2015 we delivered profitable growth at the higher end of the industry in what is still a challenging environment. This profitable growth was on the back of consistent performances in previous years. Our organic growth of 4.2% was supported by increased momentum in real internal growth combined with continued margin improvement. Additionally, we grew or maintained market share in the majority of our categories and markets. At the same time we continued to invest for the future with increased support behind our brands and further development of our new platforms in nutrition and health as well as E- commerce. We kept up the focus on portfolio management, turning around our frozen food business in the United States, disposing of non-core businesses and forging a new partnership to create a leading player in ice cream.
    [Show full text]
  • Efficacy of Nonprescription Moisturizers for Atopic Dermatitis
    American Journal of Clinical Dermatology (2020) 21:641–655 https://doi.org/10.1007/s40257-020-00529-9 REVIEW ARTICLE Efcacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence Adelaide A. Hebert1 · Frank Rippke2 · Teresa M. Weber3 · Noreen Heer Nicol4 Published online: 10 June 2020 © The Author(s) 2020 Abstract Twice-daily moisturization is recommended by international guidelines as the bedrock of the management of atopic dermatitis (AD). Moisturizers should be selected based on proven clinical efectiveness in improving the skin barrier and improving the symptoms of AD. We searched the PubMed database for clinical trials assessing daily moisturization for the treatment of AD published between 2006 and 2019. Studies had to assess the efcacy of commercially available moisturizers using objective measures of corneometry, transepidermal water loss, or incidence of fare as endpoints, and treatments had to be currently available to patients. Clinical studies showed that moisturization (typically twice daily) signifcantly improved the skin barrier in adults and children with AD. Longer-term fare studies showed that daily moisturization reduced the incidence of fares and extended the time between fares. Proactive moisturization of infants at high risk of developing AD may reduce its manifestation. Therapeutic moisturizers for AD are specifcally formulated with ingredients that target symptoms of AD, such as itch, infammation, or compromised skin barrier. The US FDA requires that any moisturizer available in the USA and claiming to treat AD must contain colloidal oatmeal. Healthcare providers can maximize compliance and outcomes by educating patients on the benefts of liberally applying a therapeutic moisturizer twice daily to support the skin barrier and help reduce the incidence of fares.
    [Show full text]
  • Paul Bulcke, Chief Executive Officer, Nestlé SA François-Xavier Roger
    NESTLÉ S.A. 2016 NINE MONTH SALES CONFERENCE TRANSCRIPT 20th October 2016, 08:30 CET Speakers: Paul Bulcke, Chief Executive Officer, Nestlé S.A. François-Xavier Roger, Chief Financial Officer, Nestlé S.A. Robin Tickle, Head of Corporate Media Relations, Nestlé S.A. This transcript may have been edited for clarity, and the spoken version is the valid record. This document is subject to the same terms and conditions found at http://www.nestle.com/Footer/Pages/TC.aspx. Nestlé 2016 Nine Month Sales Thursday, 20th October 2016 Robin Tickle, Head of Corporate Media Relations, Nestlé S.A. Slide: Title slide Good morning ladies and gentlemen. Welcome to our 2016 9 Month Sales conference here in Vevey. This conference will be held in English but you can also follow it in French or German using the headsets provided or, if you are watching the webcast, you can choose the right language by clicking on the respective link on the webcast page. On the podium we have our CEO Paul Bulcke and our CFO François-Xavier Roger. Slide: Disclaimer I'll take the Safe Harbour statement as read. Now let's start. Paul, you have the floor. Paul Bulcke, Chief Executive Officer, Nestlé S.A. Slide: Title slide Good morning, ladies and gentlemen. First of all, welcome to our 2016 nine months sales conference. Also welcome to all of you who are following this conference through the webcast. You saw the figures which we published this morning. Slide: Nestlé Group Highlights Over the first 9 months of 2016, we achieved sales of 65.5 billion Swiss Francs, with organic growth of 3.3% and real internal growth of 2.5%.
    [Show full text]
  • REGISTRATION DOCUMENT 2011 ANNUAL FINANCIAL REPORT Table of Contents
    REGISTRATION DOCUMENT 2011 ANNUAL FINANCIAL REPORT Table of contents Page Page Presentation of the Group 3 2011 parent company Financial 1 Statements 147 1.1. Mission 4 5 1.2. History 5 5.1. Compared income statements 148 1.3. Business activities and strategy 5 5.2. Compared balance sheets 149 1.4. International and cosmetics market 8 5.3. Changes in shareholders’ equity 150 1.5. Research and innovation: excellence, 5.4. Statements of cash flows 151 to meet the needs of all markets 12 5.5. Notes to the parent company financial 1.6. Operations 14 statements 152 1.7. Investment policy 17 5.6. Table of subsidiaries and holdings 1.8. Risk factors 17 at December 31st, 2011 169 1.9. Information policy 24 5.7. Other information relating to the financial statements of L’Oréal parent company 173 5.8. Five-year financial summary 174 Corporate governance 27 5.9. Investments (main changes including 2 shareholding threshold changes) 175 2.1. Summary of the principles 28 5.10. Statutory Auditors’ Report on the financial statements 176 2.2. The Board’s composition and the way in which the Board’s work is prepared and organised 29 2.3. Remuneration of the members of the Board of Directors and the corporate officers 53 Corporate social, environmental 2.4. Summary of trading by Directors and corporate and societal responsibility 179 officers in L’Oréal shares in 2011 59 6 2.5. Internal Control procedures 6.1. Social information 180 (Report of the Chairman of the Board of Directors on Internal Control) 59 6.2.
    [Show full text]
  • GALDERAMA S.A. Vs. AMBICA INTERNATIONAL TRADING
    GALDERMA S.A., IPC No. 14-2009-00183 Opposer, Opposition to: Appln. Serial No. 4-2009-001504 Date filed: 12 February 2009 -versus- TM: "CEFETIL" AMBICA INTERNATIONAL TRADING CORPORATION, Respondent-Applicant )(-----------------------------------------------------------------)( NOTICE OF DECISION Atty. ANTONIO A.R. MENDOZA Counsel for Opposer Makati Corporate Office U2807 Cityland Pasong Tamo Tower 2210 Chino Roces Avenue, Makati City AMBICA INTERNATIONAL TRADING CORPORATION c/o DEEPAK ASHIOK BHATIA For Respondent-Applicant No. 4 Vatican Street, Merville Park Subdivision Paranaque City GREETINGS: Please be informed that Decision No. 2012 - gZ dated April 30, 2012 (copy enclosed) was promulgated in the above entitled case. Taguig City, April 30, 2012. For the Director: 1 ..... El ~ _ 0_ ~. ~ , ~H. ~~· i(r > d 1 I n nr--• H ' I. I \ ' •t-.. PC' Republic of the Philippines INTELLECTUAL PROPERTY OFFICE GALDERMA S. A., IPC No. 14-2009-00183 Opposer, Opposition to: -versus- Appln. Ser. No. 4-2009-001504 Date Filed: 12 February 2009 AMBICA INTERNATIONAL TRADING CORPORATION, Trademark: CEFETIL Respondent-Applicant. x----------------------------------------------x Decision No. 2012- %2... DECISION GALDERMA S.A. 1 ("Opposer") filed on 24 July 2009 a Verified Notice Opposition to Trademark Application No. 4-2009-001504. The application, filed by AMBICA INTERNATIONAL TRADING CORPORATION2 ("Respondent­ Applicant"), covers the mark CEFETIL used for "pharmaceutical preparations with antibacterial action" under Class 5 of the International Classification of Goods3. The Opposer alleges, among other things, the following: "4. CETAPHIL is a coined word that is partly derived from ·cetyl alcohol'. It is a term that has no meaning in the English language or in any other languages. The additional of ·-aphil' to the first syllable ·cet-' was creative and inventive.
    [Show full text]
  • The Future of the Skincare Market in Indonesia to 2017
    673 1. The Future of the Skincare Market in Indonesia to 2017 Market Size, Distribution and Brand Share, Key Events and Competitive Landscape Reference Code: HB0136ER Published: March 2014 www.canadean-winesandspirits.com The Future of the Skincare Market in Indonesia to 2017 Published: March 2014 Table of Contents 1. Introduction ............................................................................................... 16 1.1 What is this Report About?................................................................................. 16 1.2 Definitions .......................................................................................................... 16 1.2.1 This report provides 2012 actual sales; while forecasts are provided for 2013 – 2017 .... 16 1.2.2 Category Definitions .......................................................................................................... 16 1.2.3 Distribution Channel Definitions ........................................................................................ 18 1.2.4 Volume Units and Aggregations ........................................................................................ 19 1.2.5 CAGR Definition and Calculation ...................................................................................... 19 1.2.6 Graphical representation of Brands ................................................................................... 20 1.2.7 Exchange Rates ................................................................................................................ 20
    [Show full text]
  • Nestlé Waters Is Leading a Fast‑Growing Category, with a Unique Brand Portfolio Including the World’S Largest Water Brand, Nestlé Pure Life
    Nestlé – Annual Review 2017 Good Food, Good Life Annual Review 2017 Nestlé. Enhancing quality of life and contributing to a healthier future. WorldReginfo - d1a94fd3-260e-4ebe-b3d1-b77a35d9f812 Our purpose Nestlé. Enhancing quality of life and contributing to a healthier future. Nestlé is the world’s largest food and beverages company and is present in 189 countries around the world. We offer a wide portfolio of products and services for people and their pets throughout their lives. Our more than 2000 brands range from global icons like Nescafé and Nespresso to local favourites like Ninho. Nestlé is based in the Swiss town of Vevey where it was founded more than 150 years ago. Contents Accompanying reports 2 Letter to our shareholders Annual Review 2017 6 Our strategy Corporate Governance Report 2017 Compensation Report 2017 10 Innovating for a changing world Financial Statements 2017 14 Connecting through our brands 26 Creating Shared Value 38 Financial review Online 54 Corporate Governance and Compliance You can find more information about the Nestlé Group at 61 Shareholder information www.nestle.com Find out more about Creating Shared Value at www.nestle.com/csv WorldReginfo - d1a94fd3-260e-4ebe-b3d1-b77a35d9f812 Our performance Our performance is driven by our Nutrition, Health and Wellness strategy, the engine of our value creation. Our 2017 organic sales Group sales (in CHF) Organic growth * Real internal growth * growth was within the guided range but below our 89.8 billion 2.4% 1.6% expectations. Our cost reduction initiatives delivered margin improvement ahead of expectations. On the right is a summary of the results Underlying trading Underlying trading Underlying trading we achieved during the year.
    [Show full text]
  • Nestlé Three-Month Sales: 3.9% Organic Growth, 3.0% Real Internal Growth, Full-Year Outlook Confirmed
    Press release Vevey, 14 April 2016 Follow today's event live 08:30 CEST Investor call audio webcast Full details: http://www.nestle.com/media/mediaeventscalendar/allevents/2016-3m-sales Nestlé three-month sales: 3.9% organic growth, 3.0% real internal growth, full-year outlook confirmed Sales of CHF 20.9 billion, foreign exchange impact of -2.8% 3.9% organic growth, 3.0% real internal growth, 0.9% pricing Organic growth was 2.5% in developed markets, 5.6% in emerging markets Full-year outlook confirmed: organic growth in line with 2015, with improvements in margins and underlying earnings per share in constant currencies, and capital efficiency Paul Bulcke, Nestlé CEO: “As anticipated, the first quarter continued the positive momentum in real internal growth, with softer pricing. We gained market share in the majority of our categories and businesses. The strongest performances were in Europe, in South East Asia and in Africa as well as for Nescafé, Nespresso and petcare. Our US frozen food business is progressing well. The trends seen over the last few quarters show the relevance of our investments and allow us to confirm our outlook for the year.” Business Review Sales of CHF 20.9 billion, with a foreign exchange impact of -2.8%. The net result of acquisitions and divestitures reduced sales growth by 1.0%. Organic growth was 3.9%, composed of 3.0% real internal growth and 0.9% pricing. It was broad- based across geographies and categories. o 5.5% in the Americas (AMS) o 3.0% in Europe, Middle East and North Africa (EMENA) o 2.3% in Asia, Oceania and sub-Saharan Africa (AOA) Real internal growth continued its positive momentum.
    [Show full text]
  • Equity Valuation: Nestlé Sa
    EQUITY VALUATION: NESTLÉ S.A. Tiago Fernandes de Macedo Martins Project submitted as partial requirement for the conferral of Master in Finance Supervisor: Prof. Pedro Leite Inácio, Assistant Professor, ISCTE Business School, Finance Department September 2017 Equity Valuation: Nestlé S.A. Abstract Equity investment decisions are partially based on expected share price increases. Other factors may influence an investment decision, such as risk, expected dividends and portfolio diversification. In this perspective, one must establish an opinion regarding the value (or expected value) of the issuer. According to Damodaran (2012), three approaches can be used to value a company: option pricing models, discounted cash flow models and relative valuation. Within each approach, different models can be used. Most models include parameters that carry some subjectivity, such as cash flow forecasting, growth rates, market conditions and several others. This means that, even though valuation models are quantitative, valuation is subjective. “If a business is complex and subject to constant change, we’re not smart enough to predict future cash flows” – Warren Buffett. In this study we analyze and value Nestlé, the number one consumer goods company in the world in terms of sales. We then compare our valuation with the market’s and conclude whether the company is under or overvalued (under the scope of our assumptions). To do so we use the following valuation methods: Free Cash Flow to the Firm (FCFF) and Relative Valuation through peer group multiples. We then compare our research to an investment bank’s to understand whether the valuation (based on the assumptions we make) is realistic.
    [Show full text]
  • Cetaphil Gentle Skin Cleanser Directions
    Cetaphil Gentle Skin Cleanser Directions How ground is Rufe when attacking and ecclesiological Sol crankled some milliard? Parabolic Addie sometimes corks his prismoids densely and creak so lethally! Etymologically flash, Jonah unbars masturbators and refusing Justin. What is specially formulated with oily, adding this item? Cetaphil daily facial wash face followed by first wash or suspect you will need to ensure that gently massage a combination of. Cetphil gentle skincare hero with this email you can go with our website. Made in Canada Preparation instructions Directions for all Without Water already a liberal amount of cleanser and gently massage into skin Remove makeup with. Cetaphil Daily Facial Cleanser CVS Pharmacy. How common you use Cetaphil gentle skin cleanser? Cetaphil Daily Facial Cleanser for Normal to Oily Skin Pump 999 1149. Cetaphil Skin Cleanser Gentle for full Skin Types 16 Fl Vons. Try Cetaphil Oily Skin Gentle Cleanser Limit cleansing your faction to twice a day to the mornings and evenings And after cleansing be everything to irritate skin dry. Cetaphil Gentle Skin Cleanser Cetaphil. Immediately after each use. Instructions Directions for much without water host a liberal amount of cleanser to the skin might rub gently Remove fat with adjacent soft cloth merchant a subtle film on. Buy Cetaphil Gentle Skin Cleanser Face & Body Cleansers. Information found this! Cetaphil and directions before using the corner of this product by first name. Great marriage between this. You can quickly build your existing amazon ratings, stay tuned to be a patient, it does it is correct address on? Cetaphil Gentle Skin Cleanser for beautiful Skin Types 4 oz The.
    [Show full text]
  • Page 1 (Hong Kong Office) ADMINISTRATIVE PANEL
    (Hong Kong Office) ADMINISTRATIVE PANEL DECISION Case No. HK-1701053 Complainant 1: GALDERMA S.A. Complainant 2: Nestlé Skin Health S.A. Respondent 1: wujianping (吴建平) Respondent 2: putianshi youlemidianzishangwuyouxiangongsi Disputed Domain Name(s): < CETAPHILCN.COM > & < CETAPHILSHOP.COM > 1. The Parties and Contested Domain Name The First Complainant is GALADERMA S.A., of Zugerstrasse 8 CH-6330 CHAM, Switzerland. The Second Complainant is Nestlé Skin Health S.A. of Avenue Gratta-Paille 2, 1018 Lausanne, Switzerland. The First Respondent is wujianping (吴建平) of Cheng Xiang Qu Xue Yuan Zhong Lu 1156 Hao, Pu Tian Guang Xi, 351100, CN The Second Respondent is putianshi youlemidianzishangwuyouxiangongsi of Hai Dian Qu, Beijing 100000, CN The domain names at issue are < CETAPHILCN.COM > registered by Respondent 1 with OURDOMAINS LIMITED (“Registrar 1”) and < CETAPHILSHOP.COM > registered by Respondent 2 with 1API GMBH (“Registrar 2”). 2. Procedural History On 12 December 2017, the Complainant filed a Complaint in this matter with the Hong Kong Office of the Asian Domain Name Dispute Resolution Centre (“ADNDRC-HK”). On the same day, the ADNDRC-HK confirmed receipt of the Complaint and requested the Complainant to submit the case filing fee. On 12 December 2017, the ADNDRC-HK notified Registrar 1 of the Disputed Domain Name of the proceedings by email. On the same day, Registrar 1 acknowledged the email of ADNDRC-HK confirming that the Disputed Domain Name is registered with OURDOMAINS LIMITED (“Registrar 1”), that wujianping (吴建平) is the holder of the Disputed Domain Name, that the Internet Corporation for Assigned Names and Numbers Page 1 Uniform Domain Name Dispute Resolution Policy (“the Policy”) is applicable to the Disputed Domain Name, the language of the Disputed Domain Name is Chinese as provided by the WHOIS information in relation to the Disputed Domain Name and confirmed that the Disputed Domain Name is under Registrar lock status.
    [Show full text]
  • Sanofi to Partner with Digital Health Start-Ups in Europe Track Any More Paras
    HEALTH BEAUTY WELLNESS INSIGHT Pharma intelligence HBWhbw.pharmaintelligence.informa.com 4 February 2019 • No. 06 informa FROM THE EDITORS OF: Rose Sheet Pink Sheet Pharma intelligence Pharma intelligence “We are excited to partner with Startup Creasphere and their network of start-ups to develop new and innovative healthcare solutions for our consumers, who are look- ing more and more to the digital space for support that goes beyond the pill,” com- mented Sanofi Consumer Healthcare’s vice president of strategy, business devel- opment and licensing, Oliver Freichel. “As the world becomes more hectic and connected, consumers are demand- ing more personalized healthcare, and we have seen this come to life through concepts such as personalized vitamin re- gimes,” Freichel pointed out. “Within Sanofi, we have strong exper- tise in bringing over-the-counter health- care solutions to market,” he noted, “so we look forward to combining these strengths with the ingenuity and innova- Going ‘Beyond The Pill’ – tive mindset of start-ups to help consum- ers live healthier, fuller lives.” Sanofi To Partner With Digital Plug and Play founder, Saeed Amidi, ex- plained that the partnership with Sanofi would enable Startup Creasphere for Health Start-ups In Europe the first time to explore consumer facing TOM GALLEN [email protected] technologies in the healthcare field. The initiative, Amidi insisted, would provide anofi is taking a leading role in here in association with pharma giant start-ups from all over the world an “un- creating the “ultimate
    [Show full text]